NASDAQ:MNKD MannKind (MNKD) Stock Forecast, Price & News $4.32 0.00 (0.00%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$4.26▼$4.4450-Day Range$3.72▼$4.7952-Week Range$2.91▼$5.73Volume2.27 million shsAverage Volume3.20 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MannKind MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.5% Upside$6.50 Price TargetShort InterestBearish14.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 4 Articles This WeekInsider TradingSelling Shares$1.84 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.14) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector752nd out of 981 stocksPharmaceutical Preparations Industry364th out of 464 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, MannKind has a forecasted upside of 50.5% from its current price of $4.32.Amount of Analyst CoverageMannKind has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.32% of the outstanding shares of MannKind have been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in MannKind has recently increased by 0.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 2.3 News and Social Media Coverage News SentimentMannKind has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MannKind this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows6 people have added MannKind to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,838,168.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.16% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.14) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -15.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -15.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MannKind (NASDAQ:MNKD) StockMannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.Read More Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Stock News HeadlinesJune 5, 2023 | americanbankingnews.comMannKind Co. (NASDAQ:MNKD) CEO Sells $45,300.00 in StockJune 2, 2023 | americanbankingnews.comMannKind (NASDAQ:MNKD) Trading Up 3.2%June 7, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 28, 2023 | fool.comMannKind (NASDAQ: MNKD)May 27, 2023 | americanbankingnews.comMannKind Co. (NASDAQ:MNKD) CFO Sells $223,272.70 in StockMay 27, 2023 | americanbankingnews.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells 95,576 Shares of StockMay 27, 2023 | americanbankingnews.comInsider Selling: MannKind Co. (NASDAQ:MNKD) CEO Sells $703,500.00 in StockMay 24, 2023 | finance.yahoo.comDr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical OfficerJune 7, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 16, 2023 | americanbankingnews.comHC Wainwright Analysts Boost Earnings Estimates for MannKind Co. (NASDAQ:MNKD)May 14, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for MannKind Co.'s Q2 2023 Earnings (NASDAQ:MNKD)May 13, 2023 | americanbankingnews.comMannKind Co. (NASDAQ:MNKD) Expected to Earn FY2024 Earnings of $0.13 Per ShareMay 13, 2023 | americanbankingnews.comMannKind (NASDAQ:MNKD) Upgraded to Buy by StockNews.comMay 13, 2023 | americanbankingnews.comFY2024 EPS Estimates for MannKind Co. Cut by Analyst (NASDAQ:MNKD)May 12, 2023 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on MannKind (MNKD)May 11, 2023 | msn.comHC Wainwright & Co. Reiterates Mannkind (MNKD) Buy RecommendationMay 10, 2023 | finanznachrichten.deMannKind: Mannkind Corporation Reports 2023 First Quarter Financial ResultsMay 10, 2023 | finance.yahoo.comMannkind Corporation Reports 2023 First Quarter Financial ResultsMay 10, 2023 | washingtonpost.comMannKind: Q1 Earnings SnapshotMay 10, 2023 | markets.businessinsider.comMannKind Corp. Q1 Loss decreases, beats estimatesMay 10, 2023 | msn.comMannKind Stock Jumps On Upbeat Q1 2023 ResultsMay 10, 2023 | finance.yahoo.comWhy Shares of MannKind Are Up WednesdayMay 10, 2023 | finance.yahoo.comMannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare ConferenceMay 10, 2023 | finance.yahoo.comMannKind (MNKD) Q1 2023 Earnings Call TranscriptMay 9, 2023 | finance.yahoo.comCORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial ResultsMay 9, 2023 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) is favoured by institutional owners who hold 54% of the companyMay 8, 2023 | americanbankingnews.comMannKind (MNKD) to Release Earnings on TuesdaySee More Headlines MNKD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNKD Company Calendar Last Earnings5/09/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees348Year Founded1991Price Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+51.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,400,000.00 Net Margins-55.45% Pretax Margin-55.45% Return on EquityN/A Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.46 Sales & Book Value Annual Sales$99.77 million Price / Sales11.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-4.53Miscellaneous Outstanding Shares264,310,000Free Float253,734,000Market Cap$1.14 billion OptionableOptionable Beta1.56 Social Links Key ExecutivesMichael E. CastagnaChief Executive Officer & DirectorLauren M. SabellaChief Operating Officer & Executive Vice PresidentSteven B. BinderChief Financial OfficerJoseph KocinskyChief Technology OfficerKevin KaisermanVice President-Medical Affairs & SafetyKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDOPKO HealthNASDAQ:OPKDynavax TechnologiesNASDAQ:DVAXInnovivaNASDAQ:INVAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsMichael CastagnaSold 10,000 sharesTotal: $45,300.00 ($4.53/share)Michael CastagnaSold 75,000 sharesTotal: $337,500.00 ($4.50/share)ProShare Advisors LLCSold 6,265 shares on 5/26/2023Ownership: 0.018%Michael CastagnaSold 150,000 sharesTotal: $703,500.00 ($4.69/share)Steven B BinderSold 47,810 sharesTotal: $223,272.70 ($4.67/share)View All Insider TransactionsView All Institutional Transactions MNKD Stock - Frequently Asked Questions Should I buy or sell MannKind stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price forecast for 2023? 1 equities research analysts have issued twelve-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2023? MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 18.4% and is now trading at $4.30. View the best growth stocks for 2023 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company earned $40.63 million during the quarter, compared to the consensus estimate of $37.40 million. The business's revenue for the quarter was up 238.8% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco DWA SmallCap Momentum ETF (DWAS), Global X Aging Population ETF (AGNG) and iShares Micro-Cap ETF (IWC). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). What is MannKind's stock symbol? MannKind trades on the NASDAQ under the ticker symbol "MNKD." Who are MannKind's major shareholders? MannKind's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.83%), State Street Corp (6.77%), Davidson Kempner Capital Management LP (0.00%), Geode Capital Management LLC (1.95%), Emerald Advisers LLC (1.38%) and Two Sigma Investments LP (1.16%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MannKind's stock price today? One share of MNKD stock can currently be purchased for approximately $4.30. How much money does MannKind make? MannKind (NASDAQ:MNKD) has a market capitalization of $1.14 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. How many employees does MannKind have? The company employs 348 workers across the globe. How can I contact MannKind? MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081. This page (NASDAQ:MNKD) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.